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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
“Appl’In® polyphenolic apple extract powder (Malus domestica)” and 
reduction of post-prandial glycaemic responses pursuant to Article 13(5) of 
Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Diana Naturals pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via 
the Competent Authority of France, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver 
an opinion on the scientific substantiation of a health claim related to “Appl’In® polyphenolic apple extract 
powder (Malus domestica)” and reduction of post-prandial glycaemic responses. The food constituent, Appl’In® 
polyphenolic apple extract powder (Malus domestica Borkh.) containing at least 5 % phloridzin, is considered to 
be sufficiently characterised in relation to the claimed effect. The Panel considers that reduction of post-prandial 
glycaemic responses (as long as post-prandial insulinaemic responses are not disproportionally increased) may be 
a beneficial physiological effect. The applicant provided one published and two unpublished human studies, three 
animal studies and two in vitro studies as pertinent to the claim. The Panel notes that the food used in one human 
study did not comply with the specifications of the food which is the subject of the claim and considers that no 
conclusion can be drawn from this study for the scientific substantiation of the claim. In two other human studies, 
post-prandial blood glucose concentrations were measured but not insulin responses. The Panel considers that no 
conclusions can be drawn from these studies for the scientific substantiation of the claim. The Panel concludes 
that a cause and effect relationship has not been established between the consumption of Appl’In® and reduction 
of post-prandial glycaemic responses. © European Food Safety Authority, 2011 
KEY WORDS 
Apple, polyphenolic extract, phloridzin, post-prandial glycaemic response, health claim. 
                                                     
1  On request from the Competent Authority of France following an application by Diana Naturals, Question No EFSA-Q-
2011-00190, adopted on 14 September 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims for the preparatory work on 
this scientific opinion: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. 
 
Appl’In® and reduction of post-prandial glycaemic responses 
 
 
2 EFSA Journal 2011;9(10):2383 
SUMMARY 
Following an application from Diana Naturals, submitted pursuant to Article 13(5) of Regulation (EC) 
No 1924/2006 via the Competent Authority of France, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to 
Appl’In® polyphenolic apple extract powder and reduction of post-prandial glycaemic responses. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence and including a request for the protection of proprietary data. 
The food constituent which is the subject of the claim, is Appl’In®, a polyphenolic extract powder of 
apple, standardised for its content in phloridzin, which is proposed by the applicant to be the active 
ingredient. The Panel considers that the food Appl’In® polyphenolic apple extract powder (Malus 
domestica Borkh.) containing at least 5 % phloridzin, which is the subject of the claim, is sufficiently 
characterised in relation to the claimed effect.  
The claimed effect proposed by the applicant relates to the reduction of post-prandial glycaemic 
responses. The target population proposed for the claim is healthy women in the general population 
willing to reduce their glycaemic response. The Panel considers that reduction of post-prandial 
glycaemic responses (as long as post-prandial insulinaemic responses are not disproportionally 
increased) may be a beneficial physiological effect. 
The applicant provided one published and two unpublished human intervention studies, three animal 
studies and two in vitro studies as pertinent to the claim. 
The food used in one human intervention study did not comply with the specifications of the food 
which is the subject of the claim. The Panel considers that no conclusion can be drawn from this study 
for the scientific substantiation of the claim.  
In two other human intervention studies, post-prandial blood glucose concentrations were measured 
but not insulin responses. The Panel considers that no conclusions can be drawn from these studies 
for the scientific substantiation of the claim.  
Animal and in vitro studies were provided on the effect of phloridzin on glucose transport and 
absorption. The Panel considers that human studies are required for the substantiation of a claim, and 
that evidence provided in animal and in vitro studies is not sufficient to predict the occurrence of an 
effect of apple polyphenol extract powder consumption on reduction of post-prandial glycaemic 
responses in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of Appl’In® and reduction of post-prandial glycaemic responses. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health), which are based on newly developed 
scientific evidence or include a request for the protection of proprietary data, to the Community list of 
permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Art 13(3) shall be submitted by the applicant to the national competent 
authority of a Member State, which will make the application and any supplementary information 
supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA: 
 The application was received on 04/03/2011. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence and including a request for the protection of proprietary data. 
 On 10/03/2011, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 The applicant provided the missing information on 26/04/2011. 
 The scientific evaluation procedure started on 30/04/2011. 
 During the meeting on 14/09/2011, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to Appl’In® 
polyphenolic apple extract powder and reduction of post-prandial glycaemic responses. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: “Appl’In® polyphenolic apple 
extract powder (Malus domestica)” and reduction of post-prandial glycaemic responses. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of “Appl’In®”, a positive assessment of its safety, nor a decision on whether “Appl’In®” is, or is not, 
classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework 
of Regulation (EC) No 1924/2006. 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. Official Journal of the European Union OJ L 404, 30.12.2006. Corrigendum OJ L 12, 
18.1.2007, p. 3–18. 
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It should also be highlighted that the scope, the proposed wording of the claim and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Diana Naturals BP15, 35560 ANTRAIN (France). 
The application includes a request for the protection of proprietary data in accordance with Article 21 
of Regulation (EC) No 1924/2006 for two unpublished study reports (Mireaux and Schmitt, 2007, 
unpublished; Schmitt and Mireaux, 2008, unpublished). 
Food/constituent as stated by the applicant 
According to the applicant, the food constituent for which the claim is made is “Appl’In®, 
polyphenolic apple extract powder (Malus domestica)”. 
Health relationship as claimed by the applicant 
According to the applicant, an intake of 25 mg of Appl’In® per gram of sucrose leads to a reduction in 
the incremental area under the curve for blood glucose levels over 2 hours in females with a BMI 
between 20 and 28.3 kg/m². The action of Appl’In® on glucose metabolism is proposed to be mainly 
due to its content in phloridzin. Phloridzin is a strong inhibitor of the transport of glucose in the 
intestine (Ehrenkranz et al., 2005). Less glucose reaches the blood stream, decreasing the glycaemic 
response after glucose intake.  
Wording of the health claim as proposed by the applicant 
The applicant proposes the following wording: “Appl’In® contributes to decrease glycaemic response 
in women”. 
Specific conditions of use as proposed by the applicant 
The target population proposed by the applicant is healthy women in the general population willing to 
reduce their glycaemic response.  
The applicant proposes that the daily quantity and pattern of consumption required to obtain the 
claimed effect is 25 mg of Appl’In® per gram of sucrose to be consumed with or added to a snack 
(food or drink), as the unpublished clinical trial was carried out with this dose.  
ASSESSMENT  
1. Characterisation of the food/constituent 
The food constituent which is the subject of the claim is Appl’In®. 
Appl’In® is a fine powder of a polyphenolic extract from apple (Malus domestica Borkh.), soluble in 
water (85 to 95 % at a 10 % concentration), which is proposed to be used in capsules or tablets or 
added to foods or drinks. The specified total polyphenol content is 80 % of the final product 
expressed as catechin equivalents based on light absorption at 280 nm. The Panel notes that this 
method is not specific for polyphenols because other compounds such as proteins and nucleic acids 
will also be included in the quantification, thus leading to an overestimation of the actual polyphenol 
content. However, the Panel considers that, given the standardised manufacturing process and the 
final standardisation on the phloridzin content, this method is acceptable as an additional 
standardisation tool. 
Appl’In® and reduction of post-prandial glycaemic responses 
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The major polyphenol constituents of Appl’In® are identified and quantified by HPLC so that the 
product can be standardised as having at least 5 % phloridzin, which is claimed to be the active 
component. Stability of Appl’In® has been tested.  
In addition to polyphenols, the extract contains 4.8 % proteins, 4.0 % sugars, 4.5 % dietary fibre, of 
which 2.8 % is soluble fibre and 1.8 % insoluble fibre, and 150 mg sodium per 100 g, and has an 
energy content of 46 kcal/100 g. The analyses of four batches were provided and establish the 
reproducibility of the manufacturing process. 
The Panel considers that the food, Appl’In® polyphenolic apple extract powder (Malus domestica 
Borkh.) containing at least 5 % phloridzin, which is the subject of the claim, is sufficiently 
characterised in relation to the claimed effect.  
2. Relevance of the claimed effect to human health 
The claimed effect is “contributes to decrease glycaemic response in women”. The target population 
proposed by the applicant is women in the general population willing to reduce their glycaemic 
response. 
Elevation of blood glucose concentrations after consumption of a food and/or meal is a normal 
physiological response which varies in magnitude and duration and may be influenced by the 
chemical and physical nature of the food or meal consumed, as well as by individual factors (Venn 
and Green, 2007). Decreasing post-prandial glycaemic responses may be beneficial to individuals 
with, for example, impaired glucose tolerance as long as post-prandial insulinaemic responses are not 
disproportionally increased. Impaired glucose tolerance is common in the general population of 
adults. 
The Panel considers that the reduction of post-prandial glycaemic responses (as long as post-prandial 
insulinaemic responses are not disproportionally increased) may be a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect 
The applicant searched 10 databases using different combinations of terms. The use of defined 
inclusion and exclusion criteria led to the identification of one pertinent published human study 
(Johnston et al., 2002). Two other unpublished human studies claimed as proprietary by the applicant 
were also provided as being pertinent to the application (Mireaux and Schmitt, 2007, unpublished; 
Schmitt and Mireaux, 2008, unpublished) as well as three animal studies and two in vitro studies 
(Besnard et al., 2008; Ikumi et al., 2008; Katsuno et al., 2007; Pajor et al., 2008; Takii et al., 1997). 
The study by Johnston et al. (2002) was a single-blind, randomised, cross-over study in which nine 
subjects consumed, in a random order, a single dose (400 mL) of a control beverage, of a clear apple 
juice and of a cloudy apple juice in fasting conditions. Beverages were standardised to contain the 
same amount of sugars but differed in their phloridzin content. The Panel notes that the pectin content 
in the apple juice, which could have an impact on the claimed effect (EFSA Panel on Dietetic 
Products Nutrition and Allergies (NDA), 2010), was not reported. The Panel notes that the product 
used in this study does not comply with the specifications of the product that is the subject of the 
claim, and considers that no conclusion can be drawn from this study for the scientific substantiation 
of the claim. 
The study by Mireaux and Schmitt (2007, unpublished) was a pilot, single-blind, placebo-controlled, 
cross-over study which investigated the effects of a single dose of 1.25 g of Appl’In® (equivalent to 
78 mg phloridzin, 1.25 g of talc were used as placebo) on post-prandial blood glucose concentrations 
in 10 healthy adults. Appl’In® and placebo were consumed either 30 min before or together with 50 g 
of glucose on a single occasion in fasting conditions. Blood glucose concentrations were determined 
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immediately before and up to 120 minutes after consumption of glucose. The Panel notes that insulin 
responses were not assessed. The Panel considers that no conclusions can be drawn from this study 
for the scientific substantiation of the claim.  
The study by Schmitt and Mireaux (2008, unpublished) was a double-blind, placebo-controlled, 
cross-over study which investigated the effect of 250 mg of Appl’In® (equivalent to 14 mg 
phloridzin), 1.25 g of Appl’In® (equivalent to 70 mg phloridzin) or microcrystalline cellulose 
(placebo) in capsules, on post-prandial blood glucose concentrations in 18 adults (16 female). 
Appl’In® and placebo were consumed 15 min before administration of 50 g of sucrose, each on a 
single occasion, in fasting conditions. Blood glucose concentrations were determined before and up to 
120 min after consumption of sucrose. The Panel notes that insulin responses were not assessed. The 
Panel considers that no conclusions can be drawn from this study for the scientific substantiation of 
the claim.  
Five animal and in vitro studies which assessed the effect of phloridzin on glucose transport and 
absorption (Besnard et al., 2008; Ikumi et al., 2008; Katsuno et al., 2007; Pajor et al., 2008; Takii et 
al., 1997), have been provided. The Panel considers that human studies are required for the 
substantiation of a claim, and that evidence provided in animal and in vitro studies is not sufficient to 
predict the occurrence of an effect of Appl’In® consumption on post-prandial glycaemic responses in 
humans.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of Appl’In® and reduction of post-prandial glycaemic responses. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, Appl’In® polyphenolic apple extract powder containing at least 5 % phloridzin, 
which is the subject of the claim, is sufficiently characterised in relation to the claimed effect. 
 The claimed effect proposed by the applicant relates to the reduction of the post-prandial 
glycaemic responses. The target population proposed for the claim is healthy women in the 
general population willing to reduce their glycaemic response. Reduction of post-prandial 
glycaemic responses (as long as post-prandial insulinaemic responses are not 
disproportionally increased) may be a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
Appl’In® and reduction of post-prandial glycaemic responses. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on “Appl’In® polyphenolic apple extract powder (Malus domestica)” and 
reduction of post-prandial glycaemic responses pursuant to Article 13(5) of Regulation (EC) No 
1924/2006 (Claim serial No: 0296_FR). April 2011. Submitted by Diana Naturals. 
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GLOSSARY / ABBREVIATIONS 
BMI  Body Mass Index 
HPLC  High performance liquid chromatography 
